[Pharmacoeconomic assessment of prevention of the postoperative nausea and vomiting syndrome in plastic (esthetic and reconstructive) surgery].
A comparative "cost-efficiency" pharmacoeconomic analysis was made for 5 different anti-emitting drugs, i.e. for "Navoban", "Zofran" (intravenous administration, 8 mg; and suppositories, 16 mg) and for "Metipred" (methylprednisolone) used in aesthetic and reconstructive surgeries of 86 patients. All the drugs were found to be effective for the prevention of PONV. Clinically, the efficiency decreased in the following order: "Novoban" and "Zofran" suppositories 16 mg, "Metiored" and "Zofran" intravenous administration 8 mg. As for "cost-efficiency", preference should be given to "Metipred".
Pavlova
Z Sh
ZSh
Gallinger
E Iu
EIu
Mizikov
V M
VM
Svetlov
V A
VA
D000328:Adult; D000771:Anesthesia, Intravenous; D000932:Antiemetics / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D008297:Male; D020250:Postoperative Nausea and Vomiting / Q000191:economics / Q000517:prevention & control*; D019651:Plastic Surgery Procedures / Q000191:economics*
D000932:Antiemetics